Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.
Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.
As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.
Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
Drugs is able to host a range of digital features, with a number of options available to authors.